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Abstract
Previous work has shown increased insulin sensitivity, increased hepatic insulin clearance and lower postprandial insulin
responses following treatment with resistant starch, a type of dietary fibre. The objective of this study was to further
explore the effects of resistant starch on insulin secretion. Twelve overweight (BMI 28.260.4 kg/m2) individuals
participated in this randomized, subject-blind crossover study. Participants consumed either 40 g type 2 resistant starch
or the energy and carbohydrate-matched placebo daily for four weeks. Assessment of the effect on insulin secretion was
made at the end of each intervention using an insulin-modified frequently sampled intravenous glucose tolerance test
(FSIVGTT). Insulin and C-peptide concentrations were significantly higher during the FSIVGTT following the resistant
starch compared with the placebo. Modelling of the data showed significantly improved first-phase insulin secretion with
resistant starch. These effects were observed without any changes to either body weight or habitual food intake. This
study showed that just four weeks of resistant starch intake significantly increased the first-phase insulin secretion in
individuals at risk of developing type 2 diabetes. Further studies exploring this effect in individuals with type 2 diabetes
are required.
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Introduction
Over recent years the incidence of type 2 diabetes has increased
and with this rise there is an associated increase in treatment
strategies to help combat the problem. Those that help to prevent
the development of impaired glucose tolerance (often referred to as
pre-diabetes) and the progression from pre-diabetes to diabetes are
clearly important.
Currently, the recommendation for treatment of pre-diabetes is
with diet and lifestyle modifications and annual screening for
progression to diabetes (ADA Guidelines, 2011) [1]. In some cases
where there are co-morbidities or where an individual is at high
risk of developing diabetes (such as individuals with a strong family
history or who are obese), individuals may be treated with
metformin (ADA Guidelines, 2011) [1]. Clearly, any dietary
intervention that can help to improve insulin secretion or
sensitivity and glucose control would be of value.
Loss of first-phase insulin secretion has been well characterised
as a primary defect in the development of type 2 diabetes [2,3].
Restoration and improvement of first-phase insulin secretion is an
important target in the treatment of type 2 diabetes and is a major
property of sulphonylureas which have been shown in some
studies to almost double the first-phase insulin response [4,5].
Several studies have shown that consumption of a non-viscous
dietary fibre in the form of resistant starch (RS) may affect glucose
and insulin concentrations when matched with controls of
identical glycaemia [6–9]. A previous study by our group in
individuals with insulin resistance (pre-diabetes) demonstrated that
consumption of 40 g/day type 2 RS derived from high amylose
maize (HAM-RS2) for 12 weeks increased tissue insulin sensitivity
by 19%, compared with an energy and carbohydrate-matched
placebo [9]. Our group has shown a reduced postprandial insulin
response following acute (24 hours) ingestion of HAM-RS2 [6];
whilst the study showed an increased C-peptide:insulin ratio,
implying improved hepatic insulin clearance, the study design did
not provide information as to whether consumption of RS might
affect insulin secretion. The current study was therefore designed
to further explore the effect of HAM-RS2 utilising an insulin-
modified frequently sampled intravenous glucose tolerance test
(FSIVGTT) to determine whether the effects of RS are due to
improvements in insulin secretion or clearance.
Methods
A total of 12 overweight individuals (8 males and 4 females;
mean age 3764.0 years, BMI 28.260.4 kg/m2) with insulin
resistance (fasting insulin 9669.7 pmol/l) as defined by the
European Group for the Study of Insulin Resistance (EGIR)
criteria [10], but without a diagnosis of T2DM were recruited.
These diagnostic criteria were chosen as the most discriminating
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for the presence of insulin resistance [11]. The participants had no
history of gastrointestinal disease and were not following any
dietary restrictions. The study commenced in 2008 and was
conducted according to the guidelines laid down in the Declara-
tion of Helsinki, and all procedures were approved by the Surrey
NHS Research Ethics Committee (REC reference 08/H1109/
112) and the University of Surrey Research Ethics Committee
(EC/2008/80/FHMS). Written informed consent was obtained
from all participants.
The study was a subject-blind, randomised crossover study.
Participants consumed either 67 g Hi-maize 260H (60% resistant
starch and 40% rapidly digestible starch (RDS) providing 40 g
HAM-RS2 as measured by The Association of Official Analytical
Chemists for total dietary fibre method 991?43) or 27 g AmiocaH
(100% RDS) daily for 4 weeks, separated by a 4 week washout
period. Both supplements were supplied by the National Starch
Company, LLC (Bridgewater, NJ, USA) in ready-to-use sachets
that simply required mixing into a cold liquid.
During the final week of each intervention, participants
completed 7-day dietary records to assess food intake and a 7-
day bowel habit and symptom diary to assess gastrointestinal
tolerance of the supplements.
At the end of each intervention, participants attended the
CEDAR Centre at the Royal Surrey County Hospital for an
insulin-modified frequently sampled intravenous glucose tolerance
test (FSIVGTT). Participants arrived fasting and following
voiding, body weight and composition were measured by
bioimpedance (Tanita, Arlington Heights, IL, USA). Blood
pressure was taken after resting for 5 minutes, and the mean of
3 readings was recorded (Omron MX3 Plus, Omron Healthcare
Europe, Milton Keynes, United Kingdom).
An indwelling intravenous cannula was inserted into each arm,
one for sampling and the other for infusion. At time zero, a glucose
bolus was administered at a dose of 0.3 g/kg body weight
(maximum dose of 25 g glucose) over 5 minutes, followed, at time
20 minutes, by a bolus of insulin (Actrapid, Novo Nordisk
Denmark) at a dose of 0.03 U/kg body weight given over
5 minutes. Frequent blood samples were taken (a total of 29
samples) for a total of 3 hours.
Blood glucose concentrations were measured immediately using
the YSI 2300 STAT PlusTM (YSI Life Sciences, UK). Plasma
insulin and C-peptide concentrations were measured by radioim-
munoassay using commercially available kits (Millipore, Billerica,
MA), inter-assay CV ,10%. Fasting plasma lipid concentrations
were measured using commercially available kits, triacylglycerides
(TAG) and total cholesterol using IL Test kits (Insturmentation
laboratory, UK); and non-esterified fatty acids (NEFA) using
RANDOX kits (RANDOX Laboratories Ltd, UK), for the
ILab650 (Instrumentation Laboratory, UK).
All statistical analyses were carried out using SPSS 16.0 for
Windows (Chicago, USA). Statistical significance was taken as
p,0.05. The raw glucose, insulin and C-peptide data were
analysed using repeated measures ANOVA. The data were also
modelled using Bergman’s minimal model (MINMOD Millenni-
um version), which has been described by Boston et al [12]. All
results are expressed as mean 6 SEM.
Results
Both HAM-RS2 and placebo were well tolerated as reported in
the bowel habit and symptom diaries. There were no significant
differences between the HAM-RS2 and placebo for body weight,
adiposity, waist circumference or blood pressure (Table 1). Fasting
glucose concentrations were significantly lower following 4 weeks
supplementation with HAM-RS2 compared with placebo
(p = 0.049), but there were no significant differences between the
supplements for fasting insulin, C-peptide or lipid concentrations
(Table 1).
Analysis of the 7-day dietary records revealed no significant
differences between theHAM-RS2 and placebo for either energy or
macronutrient intakes. Fibre intake was significantly higher during
the HAM-RS2 intervention compared with the placebo
(57.861.2 g/day versus 17.561.6 g/day, respectively;
p=,0.001) which can be directly attributed to the HAM-RS2
supplement.
Blood glucose concentrations during the FSIVGTT were not
significantly different following supplementation with either
HAM-RS2 or placebo (Figure 1). However, plasma insulin
(Figure 2) and C-peptide (Figure 3) concentrations were signifi-
cantly higher following 4 weeks supplementation with HAM-RS2
compared with placebo (p=0.009 and p=0.016, respectively).
Whilst modelling of the data showed no significant difference
between the supplements for insulin sensitivity or disposition
index, there was a significantly higher first-phase insulin response
(AIRg) following supplementation with HAM-RS2 compared with
placebo and a trend for increased glucose effectiveness with the
HAM-RS2 (Table 2).
Discussion
This study was designed to further explore the effects of HAM-
RS2 on insulin secretion. To our knowledge this is the first study to
demonstrate a significant improvement in first-phase insulin
secretion following short-term supplementation with dietary fibre
in the form of resistant starch (HAM-RS2). This work adds to our
group’s previous findings of a positive effect of HAM-RS2 on
insulin sensitivity [7,8].
Loss of first-phase insulin secretion is a well-characterised defect
in type 2 diabetes [2] and improvement in this following a simple
dietary intervention has potentially important clinical implications.
Sulphonylurea drugs have long been a mainstay in the treatment
Table 1. Anthropometric measurements and fasting plasma
concentrations taken after 4 weeks daily supplementation
with either 40 g/day of HAM-RS2 or placebo.
HAM-RS2 Placebo P value
Weight (kg) 86.8 (2.1) 87.1 (2.2) NS
BMI (kg/m2) 28.4 (0.5) 28.4 (0.5) NS
Body Fat (%)1 28.1 (2.2) 27.8 (2.2) NS
Waist Circumference (cm) 98.3 (1.2) 98.7 (1.0) NS
Systolic Blood Pressure (mmHg)2 122 (3) 120 (3) NS
Diastolic Blood Pressure (mmHg)2 77 (2) 74 (3) NS
Fasting Glucose (mmol/l) 4.8 (0.1) 5.0 (0.1) 0.049
Fasting Insulin (pmol/l) 88.6 (9.5) 85.4 (7.8) NS
Fasting C-peptide (nmol/l) 0.84 (0.1) 0.86 (0.1) NS
Fasting TAG (mmol/l) 1.6 (0.3) 1.3 (0.2) NS
Fasting NEFA (mmol/l) 0.59 (0.1) 0.48 (0.1) NS
Total Cholesterol (mmol/l) 4.8 (0.3) 4.8 (0.3) NS
All values are mean (SEM), N = 12. Comparisons made with paired t-tests.
1Measured by bioimpedance (Tanita, Arlington Heights, IL, USA). N = 11.
2Mean of 3 readings taken with the subject in a sitting position, measured by an
automatic blood pressure cuff (Omron MX3 Plus, Omron Healthcare Europe,
Milton Keynes, United Kingdom).
doi:10.1371/journal.pone.0040834.t001
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of type 2 diabetes. A study by Hosker et al [4] investigated the first
and second phase beta cell responses in individuals without
diabetes and those with type 2 diabetes controlled by diet alone.
During hyperglycemic clamps at 3 glucose levels (7.5, 10 and
15 mmol/l), the first and second phase insulin responses were
impaired in those with diabetes, and treatment with a sulphonyl-
urea (gliclazide) in those with diabetes resulted in restoration of
both the first and second phase insulin responses, with an
approximate doubling of the insulin and C-peptide response at
each level of clamp. In the current study consumption of HAM-
RS2 for 4 weeks increased the first-phase insulin response by 36%
compared with placebo treatment. The fact that this increase
approaches that seen with sulphonylurea treatment suggests that
HAM-RS2 may have potential as a strategy to prevent the
progression from impaired glucose tolerance to type 2 diabetes
and, indeed, in the treatment of type 2 diabetes.
To our knowledge dietary fibre has been shown to increase
insulin secretion only once before. In a study by Juntunen et al [13]
8 weeks consumption of high fibre rye bread significantly
increased acute insulin secretion by 7.1% compared to 8 weeks
of white wheat bread in healthy postmenopausal women. It has
been suggested that components specific to rye bread such as
phenolic acids or tannins may be responsible; however, as HAM-
RS2 contains neither of these compounds this seems unlikely as a
mechanism.
Our study does not provide data to explain the mechanism(s) for
the effect of HAM-RS2 on insulin secretion although this is likely
to be through multi-system effects. As the improvement is similar
to that seen with sulphonylureas, it is possible that RS may work
by similar mechanisms. Sulphonylureas bind to beta cell
membrane receptors which result in the increase in insulin
secretion. Although there is no direct evidence for products of
HAM-RS2 digestion binding to beta cell membrane receptors and
Figure 1. Glucose concentrations from FSIVGTT after 4 weeks daily supplementation with 40 g HAM-RS2 or placebo. N=12, mean 6
SEM. No significant difference between the HAM-RS2 and placebo. Comparisons made with repeated measures ANOVA. Black circles = HAM-RS2;
white circles = placebo; dashed line = baseline glucose concentrations.
doi:10.1371/journal.pone.0040834.g001
Figure 2. Insulin concentrations from FSIVGTT after 4 weeks daily supplementation with 40 g HAM-RS2 or placebo. N=12, mean 6
SEM. Significantly higher concentrations following HAM-RS2 compared with placebo (p= 0.009). Comparisons made with repeated measures ANOVA.
Black circles = HAM-RS2; white circles = placebo.
doi:10.1371/journal.pone.0040834.g002
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activating signalling pathways in a similar manner to sulphonyl-
ureas, recent work in animal models with HAM-RS2 has shown
an increased pancreatic beta cell density in experimental diabetes
[14]. The increase in SCFA concentrations following fermentation
of RS may also lead to other possible mechanisms including
changes in ectopic TAG storage within the pancreas; however,
changes in ectopic TAG storage may take 12 weeks of HAM-RS2
treatment to become evident [9]. Colonic SCFA production has
been linked to increases in the secretion of incretin hormones (such
as glucagon-like peptide-1, GLP-1) from enteroendocrine cells and
therefore may be an alternative mechanism for an increase in first-
phase insulin secretion. However, whilst there are data from
rodent studies showing increases in GLP-1 following RS intake
[15–17] data confirming this effect in humans are lacking, and
indeed, one study in humans has shown that it may take a year of
increased fibre intake (increase of 20 g/day) to increase GLP-1
secretion [18]. It is therefore unlikely that increases in incretin
hormones alone are the mechanism behind the effect. Circulating
SCFA, in particular propionate, may also increase insulin
secretion through binding to PPARc receptors in adipose tissue
[19] and activating pathways similar to those of the thiazolidine-
diones [20]. Further mechanistic studies are clearly required to
investigate these potential mechanisms.
Whereas studies in obese individuals with type 2 diabetes have
shown that following bariatric surgery first-phase insulin can be
restored [21], the improvement observed in our study was
independent of any changes in body weight or lifestyle. Similarly
there were no effects on plasma lipid concentrations. These results
confirm the results of previous studies by our group in healthy
individuals and those with the metabolic syndrome [7,9], as well as
in work by other groups using different types of RS.
Although this study showed an improvement in insulin secretion
following HAM-RS2, it did not demonstrate an improvement in
insulin sensitivity which we have shown previously using the
hyperinsulinemic-euglycemic clamp [7–9]. Our group have only
previously investigated the effects of HAM-RS2 in individuals with
the metabolic syndrome once and this study was of 12 weeks
duration [9]; it may therefore be that the current study of 4 weeks
maybe too short a time frame for effects on insulin sensitivity to
occur and that the improvement in first-phase insulin secretion
may be an early step in this improvement of insulin sensitivity. The
hyperinsulinemic-euglycemic clamp is the gold-standard direct
measure of insulin sensitivity or insulin-mediated glucose disposal,
whilst the IVGTT is less robust due to the hypoglycaemia and
gluco-regulatory hormone release invoked by the insulin infusion
(as clearly seen in Figure 1), especially in those without diabetes.
However, the IVGTT may be ideally suited to the assessment of
first-phase insulin secretion. We would anticipate that an
improvement in first-phase insulin might be associated with an
improvement in insulin sensitivity; however, the time-course of this
relationship needs further investigation.
In conclusion, we have shown that a simple, inexpensive, well
tolerated, non-pharmacological dietary supplementation with
HAM-RS2 can improve first-phase insulin secretion in overweight
individuals who are at increased risk of developing type 2 diabetes.
Further studies are required to confirm these findings and to
elucidate the mechanisms. It would also warrant further investi-
gation in individuals with diabetes, as no results have been
published in humans exploring the effects of HAM-RS2 treatment
in type 2 diabetes.
Figure 3. C-peptide concentrations from FSIVGTT after 4 weeks daily supplementation with 40 g HAM-RS2 or placebo. N=12, mean
6 SEM. Significantly higher concentrations following HAM-RS2 compared with placebo (p=0.016). Comparisons made with repeated measures
ANOVA. Black circles = HAM-RS2; white circles = placebo.
doi:10.1371/journal.pone.0040834.g003
Table 2. Indices from the modelling of the data from the
IVGTT.
HAM-RS2 Placebo
P
value
Insulin Sensitivity ((mu/l)21 min21) 3.3 (0.6) 3.6 (0.5) NS
First Phase Insulin (AIRg)
(mu.l21 min)
859.9 (244.5) 634.5 (191.4) 0.009
Disposition Index 2526.5 (732.2) 2235.3 (740.6) NS
Glucose Effectiveness (min21) 0.03 (0.003) 0.02 (0.003) 0.06
All values are mean (SEM), N = 12. Comparisons made with paired t-tests.
doi:10.1371/journal.pone.0040834.t002
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